Int Arch Allergy Immunol:对乙酰氨基酚接触与过敏性鼻炎相关性的累积证据

2020-05-30 AlexYang MedSci原创

一些研究将对乙酰氨基酚与过敏性鼻炎的风险联系了起来,但是结果有矛盾。

一些研究将对乙酰氨基酚与过敏性鼻炎的风险联系了起来,但是结果有矛盾。

最近,有研究人员对PubMed、Embase、Cochrane Library和Web of Science进行了搜索,数据截止时间为2019年12月1日。分析包括了18个研究,共870492名参与者。分析表明对乙酰氨基酚与过敏性鼻炎的风险增加相关(OR: 1.54, 95%CI: 1.41-1.69)。同时,早期暴露与过去几年暴露对乙酰基苯酚与过敏性鼻炎风险呈现正相关关系(分别为OR: 1.34, 95%CI: 1.21-1.49和OR: 1.74, 95%CI: 1.48-2.04)。过敏性鼻炎的风险对那些上年每月均暴露于对乙酰基苯酚的参与者(OR: 1.90, 95%CI: 1.60-2.26)要比每年暴露一次的参与者更高(OR: 1.28, 95%CI: 1.11-1.48)。

最后,研究人员指出,他们的元分析为对乙酰基苯酚与过敏性鼻炎风险的增加相关提供了证据。另外,早年对乙酰基苯酚暴露以及上年暴露对乙酰基苯酚均与过敏性鼻炎正相关。进一步的研究需要调查上述相关性具有因果关系。

原始出处:

Yan Zeng , Bin Song , Yang Gao et al. Cumulative Evidence for Association of Acetaminophen Exposure and Allergic Rhinitis. Int Arch Allergy Immunol. 12 May 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1952072, encodeId=0d6d19520e299, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sat Dec 05 12:08:35 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047261, encodeId=7a36204e26119, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 20 21:08:35 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837836, encodeId=51c5183e836a6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 09 00:08:35 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321797, encodeId=680e1321e97e0, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329375, encodeId=83df13293e5f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1952072, encodeId=0d6d19520e299, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sat Dec 05 12:08:35 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047261, encodeId=7a36204e26119, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 20 21:08:35 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837836, encodeId=51c5183e836a6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 09 00:08:35 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321797, encodeId=680e1321e97e0, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329375, encodeId=83df13293e5f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1952072, encodeId=0d6d19520e299, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sat Dec 05 12:08:35 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047261, encodeId=7a36204e26119, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 20 21:08:35 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837836, encodeId=51c5183e836a6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 09 00:08:35 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321797, encodeId=680e1321e97e0, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329375, encodeId=83df13293e5f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1952072, encodeId=0d6d19520e299, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sat Dec 05 12:08:35 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047261, encodeId=7a36204e26119, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 20 21:08:35 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837836, encodeId=51c5183e836a6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 09 00:08:35 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321797, encodeId=680e1321e97e0, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329375, encodeId=83df13293e5f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1952072, encodeId=0d6d19520e299, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sat Dec 05 12:08:35 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047261, encodeId=7a36204e26119, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Jan 20 21:08:35 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837836, encodeId=51c5183e836a6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 09 00:08:35 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321797, encodeId=680e1321e97e0, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329375, encodeId=83df13293e5f9, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jun 01 05:08:35 CST 2020, time=2020-06-01, status=1, ipAttribution=)]
    2020-06-01 膀胱癌

相关资讯

盘点:过敏性鼻炎研究进展

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个

Ann Allergy Asthma Immunol:剖腹产与儿童过敏性鼻炎风险研究

剖腹产(C-section)可能影响婴儿肠道菌群以及免疫系统的发育,产生过敏性鼻炎(AR)的风险。最近,有研究人员调查了C-section与AR在6岁、8岁和10岁之间的相关性。

JAMA Otolaryngol Head Neck Surg: 鼻塞与过敏性鼻炎相关性分析

持续气道正压通气(CPAP)治疗后发生的鼻塞会损害CPAP的依从性。过敏性鼻炎与接触非过敏性刺激患者的鼻塞有关。CPAP的使用也代表了可能的非过敏性刺激的存在(比如湿度、温度、压力和气流)。

Int J Pediatr Otorhinolaryngol:过敏性鼻炎与抑郁、自杀意念和自杀企图相关性分析

最近,有研究人员在过敏性鼻炎(AR)青少年中评估了抑郁和自杀倾向的相关因素,分析的数据来源于韩国青少年风险行为年度网络调查(KYRBSs),时间为2007年到2017年。

Otolaryngol Head Neck Surg:布地奈德与盐水洗鼻在过敏性鼻炎治疗中的比较

布地奈德鼻洗目前广泛的应用于慢性鼻窦炎的治疗,尤其是在内镜鼻窦手术后用于改善对炎症的控制,而其在过敏性鼻炎中的治疗还未有研究。最近,有研究人员评估了过敏性鼻炎(AR)患者对布地奈德缓冲高渗盐水鼻腔冲洗

Mol Immunol: 白藜芦醇介导的SIRT1激活能够减弱卵清蛋白诱导的过敏性鼻炎

白藜芦醇(RSV)是一种具有抗炎症效果的多酚物质。而RSV对过敏性鼻炎(AR)影响情况仍旧不清楚。